This site uses cookes. By using this site you are consenting to their use according to our Cookie policy.

i agree
Unleash IMM's research excellence in immunity and infection through twinning to infect Lisbon and Portugal with its increase in competitiveness and innovation

Funding Agency European Commission
Funding Programme Horizon 2020
Call/Topic H2020-TWINN-2015 / H2020-TWINN-2015 - Twinning
Project reference 692022
Start date 2016.01.01
Duration 36 months
Total investment EUR 1 000 000 (EU contribution: EUR 1 000 000)
Project Coordinator Maria M. Mota
Project Beneficiaries
  • Instituto de Medicina Molecular João Lobo Antunes(iMM), Portugal;
  • Instituto Pasteur, France;
  • The Francis Crick Institute Limited, United Kingdom

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 692022.


TwinnToInfect will provide iMM with the opportunity to integrate the European circle of research excellence institutions by cementing a sustainable science, technology and innovation network with two internationally-leading organisations in the immunity and infection area of research, the Institut Pasteur and the Francis Crick Institute.

The strategy of TwinnToInfect, based on science- and innovation-driven clustering, is focused on this societal challenge that lies at the centre of many age-related disorders. TwinnToInfect will allow:

  1. strengthening the science and technology capacity of IMM in immunity and infection research field;
  2. and leverage its research excellence and value creation through innovation with a beneficial and quantifiable impact for the entire research and development community at IMM, the Lisbon region and Portugal.

The successful implementation of this strategy will rely on specific actions, including:

  1. cementing of existing and the creation of new scientific, innovative and technical collaborations through short-term staff exchanges and short-term on-site training activities;
  2. training, mentoring and international exposure of IMM's young researchers and students;
  3. building an innovation ecosystem centred at IMM;
  4. igniting the entrepreneurial spirit among IMM's research community;
  5. increasing science awareness among the general public through targeted dissemination and communication activities; and
  6. developing a sustainability strategy to sustain the cemented network beyond project terminus.

Through the completion of these activities, IMM, supported by Pasteur and Crick, is in the best temporal and spatial position to achieve an improved capability to compete for internationally competitive research funding and to access business stakeholders. By claiming its position in research and innovation networks IMM will effectively contribute to research excellence and value creation in health at European level.